Covid vaccine: Johnson & Johnson pauses trial after participant becomes ill
Pharma major Johnson & Johnson, which reported quarterly financial results on Tuesday morning, said that such pauses are normal in big trials, which can include tens of thousands of people. It said the study pause in giving doses of the vaccine candidate was different from a regulatory hold required by health authorities. The current case is a pause, the company stated.
The participant's illness is being reviewed and evaluated by an independent data and safety monitoring board as well as the company's clinical and safety physicians, the company said in a statement.